or Try an Advanced Search...

    Technical Analysis for CLSD - Clearside Biomedical, Inc.

    Grade Last Price % Change Price Change
    F 1.01 -0.98% -0.01
    CLSD closed down 0.98 percent on Friday, November 1, 2024, on 34 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: Nov 12
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical CLSD trend table...
    Date Alert Name Type % Chg
    Stochastic Buy Signal Bullish 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion -0.98%
    Down 3 Days in a Row Weakness -0.98%
    Oversold Stochastic Weakness -0.98%
    Older End-of-Day Signals for CLSD ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 20 hours ago
    60 Minute Opening Range Breakdown about 23 hours ago
    Down 2 % about 24 hours ago
    Down 1% about 24 hours ago
    Down 3% 2 days ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CLSD Chart by TradingView
    Basic chart:

    Profile

    Clearside BioMedical, Inc., a biopharmaceutical company, develops drug therapies to treat chronic blinding diseases of the eye. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Eye Ophthalmology Macular Degeneration Macular Edema Retina Veins Drug Therapies Wet Age Related Macular Degeneration Uveitis Adverum Biotechnologies Non Infectious Uveitis Retinal Vein Occlusion

    Is CLSD a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 31 Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024
    Oct 22 Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting
    Oct 10 Morning Movers: Arcadium Lithium surges after deal to be acquired
    Oct 9 Clearside stock falls 12% amid Phase 2 data for CLS-AX
    Oct 9 Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study
    Oct 9 Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes
    Aug 27 Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
    Aug 15 After Plunging -15.7% in 4 Weeks, Here's Why the Trend Might Reverse for Clearside Biomedical (CLSD)
    Aug 12 Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
    Aug 12 Clearside Biomedical GAAP EPS of -$0.10 beats by $0.04, revenue of $0.09M misses by $0.04M
    See more CLSD news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.12
    52 Week Low 0.7564
    Average Volume 886,429
    200-Day Moving Average 1.27
    50-Day Moving Average 1.17
    20-Day Moving Average 1.19
    10-Day Moving Average 1.11
    Average True Range 0.10
    RSI (14) 37.89
    ADX 14.53
    +DI 16.71
    -DI 22.64
    Chandelier Exit (Long, 3 ATRs) 1.35
    Chandelier Exit (Short, 3 ATRs) 1.29
    Upper Bollinger Bands 1.48
    Lower Bollinger Band 0.89
    Percent B (%b) 0.2
    BandWidth 49.58
    MACD Line -0.05
    MACD Signal Line -0.03
    MACD Histogram -0.0233
    Fundamentals Value
    Market Cap 64.25 Million
    Num Shares 63.6 Million
    EPS -0.61
    Price-to-Earnings (P/E) Ratio -1.66
    Price-to-Sales 40.85
    Price-to-Book 3.93
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.06
    Resistance 3 (R3) 1.05 1.04 1.05
    Resistance 2 (R2) 1.04 1.03 1.04 1.04
    Resistance 1 (R1) 1.02 1.02 1.03 1.03 1.04
    Pivot Point 1.01 1.01 1.01 1.01 1.01
    Support 1 (S1) 0.99 1.00 1.00 1.00 0.98
    Support 2 (S2) 0.98 0.99 0.98 0.98
    Support 3 (S3) 0.96 0.98 0.97
    Support 4 (S4) 0.97